128 related articles for article (PubMed ID: 23806538)
1. Somatostatin, estrogen, and polycystic liver disease.
Everson GT; Helmke SM
Gastroenterology; 2013 Aug; 145(2):279-82. PubMed ID: 23806538
[No Abstract] [Full Text] [Related]
2. Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data.
Gevers TJ; Inthout J; Caroli A; Ruggenenti P; Hogan MC; Torres VE; Nevens F; Drenth JP
Gastroenterology; 2013 Aug; 145(2):357-65.e1-2. PubMed ID: 23665274
[TBL] [Abstract][Full Text] [Related]
3. Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial.
Hogan MC; Chamberlin JA; Vaughan LE; Waits AL; Banks C; Leistikow K; Oftsie T; Madsen C; Edwards M; Glockner J; Kremers WK; Harris PC; LaRusso NF; Torres VE; Masyuk TV
Clin J Am Soc Nephrol; 2020 Sep; 15(9):1267-1278. PubMed ID: 32843370
[TBL] [Abstract][Full Text] [Related]
4. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.
van Aerts RMM; Kievit W; D'Agnolo HMA; Blijdorp CJ; Casteleijn NF; Dekker SEI; de Fijter JW; van Gastel M; Gevers TJ; van de Laarschot LFM; Lantinga MA; Losekoot M; Meijer E; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Visser FW; Wetzels JF; Zietse R; Gansevoort RT; Drenth JPH;
Gastroenterology; 2019 Aug; 157(2):481-491.e7. PubMed ID: 31022403
[TBL] [Abstract][Full Text] [Related]
5. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial.
Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Wetzels JF; Drenth JP
Liver Int; 2015 May; 35(5):1607-14. PubMed ID: 25369108
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin analogues improve health-related quality of life in polycystic liver disease: a pooled analysis of two randomised, placebo-controlled trials.
Neijenhuis MK; Gevers TJ; Nevens F; Hogan MC; Torres VE; Kievit W; Drenth JP
Aliment Pharmacol Ther; 2015 Sep; 42(5):591-8. PubMed ID: 26129925
[TBL] [Abstract][Full Text] [Related]
7. Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis.
Griffiths J; Mills MT; Ong AC
BMJ Open; 2020 Jan; 10(1):e032620. PubMed ID: 31924636
[TBL] [Abstract][Full Text] [Related]
8. Effect of everolimus on polycystic liver volume in autosomal dominant polycystic kidney disease.
Zschiedrich S; Budde K; Walz G
Clin Exp Nephrol; 2015 Aug; 19(4):757-8. PubMed ID: 25424440
[No Abstract] [Full Text] [Related]
9. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.
van Keimpema L; Nevens F; Vanslembrouck R; van Oijen MG; Hoffmann AL; Dekker HM; de Man RA; Drenth JP
Gastroenterology; 2009 Nov; 137(5):1661-8.e1-2. PubMed ID: 19646443
[TBL] [Abstract][Full Text] [Related]
10. Randomized intervention studies in human polycystic kidney and liver disease.
Schrier RW
J Am Soc Nephrol; 2010 Jun; 21(6):891-3. PubMed ID: 20431043
[No Abstract] [Full Text] [Related]
11. Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases.
Masyuk TV; Radtke BN; Stroope AJ; Banales JM; Gradilone SA; Huang B; Masyuk AI; Hogan MC; Torres VE; Larusso NF
Hepatology; 2013 Jul; 58(1):409-21. PubMed ID: 23172758
[TBL] [Abstract][Full Text] [Related]
12. The effects of somatostatin analogues on liver volume and quality of life in polycystic liver disease: a meta-analysis of randomized controlled trials.
Garofalo C; Capuano I; Pennino L; De Gregorio I; Riccio E; Provenzano M; Crocetto F; Buonanno P; Pandolfo SD; Andreucci M; Pisani A
Sci Rep; 2021 Dec; 11(1):23500. PubMed ID: 34873228
[TBL] [Abstract][Full Text] [Related]
13. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.
Hogan MC; Masyuk TV; Page LJ; Kubly VJ; Bergstralh EJ; Li X; Kim B; King BF; Glockner J; Holmes DR; Rossetti S; Harris PC; LaRusso NF; Torres VE
J Am Soc Nephrol; 2010 Jun; 21(6):1052-61. PubMed ID: 20431041
[TBL] [Abstract][Full Text] [Related]
14. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial.
Chrispijn M; Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Drenth JP
J Hepatol; 2013 Jul; 59(1):153-9. PubMed ID: 23499726
[TBL] [Abstract][Full Text] [Related]
15. The zebrafish as a model to study polycystic liver disease.
Tietz Bogert PS; Huang BQ; Gradilone SA; Masyuk TV; Moulder GL; Ekker SC; Larusso NF
Zebrafish; 2013 Jun; 10(2):211-7. PubMed ID: 23668934
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin analogues reduce liver volume in polycystic liver disease.
van Keimpema L; de Man RA; Drenth JP
Gut; 2008 Sep; 57(9):1338-9. PubMed ID: 18719151
[No Abstract] [Full Text] [Related]
17. Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease.
Pisani A; Sabbatini M; Imbriaco M; Riccio E; Rubis N; Prinster A; Perna A; Liuzzi R; Spinelli L; Santangelo M; Remuzzi G; Ruggenenti P;
Clin Gastroenterol Hepatol; 2016 Jul; 14(7):1022-1030.e4. PubMed ID: 26844873
[TBL] [Abstract][Full Text] [Related]
18. Lanreotide and its Potential Applications in Polycystic Kidney and Liver Diseases.
Sun L; Yu CY; Mackey LV; Coy DH
Curr Top Med Chem; 2015; 16(2):133-40. PubMed ID: 26126910
[TBL] [Abstract][Full Text] [Related]
19. Ciprofloxacin penetration into infected hepatic cysts in autosomal dominant polycystic kidney disease: a case report.
Bernts LHP; Wallenburg E; de Jonge HJM; Schaap B; Kusters R; Overtoom TTC; Brüggemann RJM; Drenth JPH; Lantinga MA
J Antimicrob Chemother; 2019 Mar; 74(3):829-830. PubMed ID: 30452619
[No Abstract] [Full Text] [Related]
20. Serum bile acids associate with liver volume in polycystic liver disease and decrease upon treatment with lanreotide.
Dekker SEI; Bierau J; Giera M; Blomberg N; Drenth JPH; Mayboroda OA; de Fijter JW; Soonawala D;
Eur J Clin Invest; 2024 Apr; 54(4):e14147. PubMed ID: 38071418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]